

# Histoplasmosis

### Alessandro C. Pasqualotto, MD PhD MBA FECMM

Porto Alegre, Brazil

Why opportunistic infections still matter in the HIV response - Part 1

Virtual meeting, April 29<sup>th</sup>, 2025




# Epidemiology

## **Rest Rest Endemic in the US**


# Areas Endemic for Histoplasmosis Highly endemic Moderately endemic Mildly endemic Suspected endemic

### **Previously**

# *<u>SIAS</u> Endemic in the US*




### Previously



### More recently

Maiga AW, et al. Emerg Infect Dis 2018; 24: 1835-9

# **RAS Histo is a global disease**



Estimated range in North, Central, and South America

Multiple cases reported

Case reports or poor-quality evidence

Thompson GR 3rd, et al. Lancet Infect Dis 2021; S1473-3099(21)00191-2



**Open Forum Infectious Diseases** 

MAJOR ARTICLE



Histoplasmosis, An Underdiagnosed Disease Affecting People Living With HIV/AIDS in Brazil: Results of a Multicenter Prospective Cohort Study Using Both Classical Mycology Tests and *Histoplasma* Urine Antigen Detection

Diego R. Falci,<sup>1,2</sup> Alexandre A. Monteiro,<sup>3</sup> Cassia Ferreira Braz Caurio,<sup>3,4</sup> Tulio C. O. Magalhães,<sup>1</sup> Melissa O. Xavier,<sup>5</sup> Rossana P. Basso,<sup>5</sup> Marineide Melo,<sup>6</sup> Alexandre V. Schwarzbold,<sup>7</sup> Paulo Roberto Abrão Ferreira,<sup>8</sup> Jose Ernesto Vidal,<sup>9</sup> João Paulo Marochi,<sup>9</sup> Cassia Silva de Miranda Godoy,<sup>10</sup> Renata de Bastos Ascenco Soares,<sup>10</sup> Aurea Paste,<sup>11</sup> Monica B. Bay,<sup>12</sup> Vera Lucia Pereira-Chiccola,<sup>13</sup> Lisandra Serra Damasceno,<sup>14</sup> Terezinha do Menino Jesus Silva Leitão,<sup>14</sup> and Alessandro C. Pasqualotto<sup>3,4</sup>

# **Relation States And Anticipation States and Anticipat**

## • 570 patients with AHD were screened

✓ 11 centres in Brazil


# **RAS Histo frequency in Brazil**


- 570 patients with AHD were screened
  - ✓ 11 centres in Brazil
- 21.6% had histoplasmosis
  - ✓Urinary antigen (IMMY Clarus) increased diagnosis by **53.8%**

Falci DR, et al. Open Forum Infect Dis 2019; 6: ofz073









#### Nacher M, et al. PLOS Negl Trop Dis 2014: 8: e3290



### Review Histoplasmosis and Tuberculosis Co-Occurrence in People with Advanced HIV

Diego H. Caceres <sup>1,2,\*,†</sup> and Audrey Valdes <sup>3,\*,†</sup>

## Labs should test for both TB and histo in advanced AIDS (median CD4 count: 30)



Caceres DH, Valdes A. J Fungi 2019; 5:73



# Clinical manifestations

**XIAS** 


#### Pleuro-pulmonary sphere Pleuro-pulmonary sphere Abdominal sphere 76/97 (78) Abdominal sphere 74/105 (70) 51/105 (49) 47/97 (48) n=33 n=32 n=8 n=12 n=25 n=29 n=12 n=2 n=5 n=8 n=2 n=6) n=9 n=2 Lymphadenopathy > 2cm Lymphadenopathy > 2cm 15/97 (15) 31/105 (29)

**Tuberculosis : clinical aspects** 

Histoplasmosis : clinical aspects

Adenis A, et al. Am J Trop Med Hyg 2014; 90: 216-23

**XIAS** 




### Tuberculosis : biological aspects

Histoplasmosis : biological aspects

Adenis A, et al. Am J Trop Med Hyg 2014; 90: 216-23



### Predictive Margins with 95% Confidence Intervals



Nacher M, et al. J Fungi 2022; 8:16



Table 1 Clinical predictors for histoplasmosis, according to different gold standards: CDC test, IMMY assay and classic methods (culture/histopathology).

	Gold standard against which variable was compared						
	IMMY®		Classic methods				
Clinical findings	OR (95% CI)	P value	OR (95% CI)	P value			
Oral ulcers	9.5 (2.) 43.0)	0.001	13.0 (2.5 68.2)	< 0.001			
Pulmonary symptoms	3.9 (0.5-32.5)	0.227	1.32 (1.2–1.5)	0.189			
Papules	7.0 (1.9-27.2)	0.002	1.8 (0.3 10.0)	0.614			
Mediastinal lymphadenopathy	3.9 (1.0–14.6)	0.035	6.0 (1.3–28.0)	0.013			

CDC, Centers for Disease Control and Prevention; CI, confidence interval; OR, odds ratio.

## **Received and Set and**



### Cunha VS, et al. Clin Experiment Dermatol 2007; 32: 250-5




# Diagnosis














## **1** Diagnosis of histoplasmosis

"Among people living with HIV, disseminated histoplasmosis should be diagnosed by detecting circulating Histoplasma antigens" (conditional recommendation; low-certainty evidence)

## *<b>RAS Meta-analysis of Ag detection*



**RESEARCH ARTICLE** 

**SIAS** 

Cost-effectiveness evaluation of routine histoplasmosis screening among people living with advanced HIV disease in Latin America and the Caribbean

Radha Rajasingham<sup>1</sup>, Narda Medina<sup>2</sup>, Gabriel T. Mousquer<sup>3</sup>, Diego H. Caceres<sup>4,5</sup>, Alexander Jordan<sup>6</sup>, Mathieu Nacher<sup>7</sup>, Diego R. Falci<sup>8,9</sup>, Ayanna Sebro<sup>10</sup>, Alessandro C. Pasqualotto<sup>11,12</sup>, Omar Sued<sup>13</sup>, Tom Chiller<sup>6</sup>, Freddy Perez<sup>11,13</sup>\*

Routine Histoplasma antigen screening <u>avoids an estimated 17%</u> of deaths in persons with advanced HIV disease, and is cost-effective compared to no histoplasmosis screening, with an <u>ICER of \$26/LYS</u>.

## **XIAS**

Impact of the introduction of a package of care involving early detection of opportunistic infections, a prospective multicenter cohort study of people living with HIV/AIDS in Brazil



Alessandro C. Pasqualotto,<sup>a,b</sup> Omar Sued,<sup>c,j</sup> Nicole Reis,<sup>a,d</sup> Larissa R. Silva,<sup>a</sup> Renata B. A. Soares,<sup>e,f</sup> Cassia S. M. Godoy,<sup>e,f</sup> Marineide G. Melo,<sup>g</sup> Nayla A. Hatem,<sup>a</sup> Bruna Regis Razzolini,<sup>d</sup> Andressa Noal,<sup>g</sup> Tarsila Vieceli,<sup>a,b</sup> Diego R. Falci,<sup>h,i</sup> and Freddy Perez<sup>a,c,j,\*</sup>

OPEN ACCESS

<sup>a</sup>Federal University of Health Sciences of Porto Alegre, R. Sarmento Leite, 245 - Centro Histórico, Porto Alegre, RS, 90050-170, Brazil
<sup>b</sup>Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil
<sup>c</sup>Pan American Health Organization (PAHO), 525 23 ST NW, Washington DC, 20037, USA
<sup>d</sup>Hospital Vila Nova, R. Catarino Andreatta, 155 - Bairro Vila Nova, Porto Alegre, RS, 91750-040, Brazil
<sup>e</sup>Hospital Estadual de Doenças Tropicais Dr Anuar Auad, Alameda do Contorno, 3556, Jardim Bela Vista, Goiânia, GO, 74850-400, Brazil
<sup>f</sup>Pontifícia Universidade Católica de Goiás, Goiânia, GO, Brazil
<sup>g</sup>Grupo Hospitalar Conceição, Av. Francisco Trein, 596 - Cristo Redentor, Porto Alegre, RS, 91350-200, Brazil
<sup>h</sup>Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350 Bloco A, Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre, RS, 90035-903, Brazil
<sup>i</sup>Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil

#### Summary

Background Opportunistic infections (OIs) significantly contribute to morbidity and mortality in advanced HIV disease. This study evaluates the efficacy of point-of-care (POC) diagnostics for tuberculosis (TB), histoplasmosis, and cryptococcosis in routine HIV care in Brazil.


Methods A prospective multicenter cohort study was conducted across five hospitals enrolling people living with HIV (PLHIV) with CD4+ T-cell count <200 cells/mm<sup>3</sup> or OI symptoms, regardless of CD4 count, HIV-naïve patients, those initiating treatment, and individuals with unsuppressed viral load lost to follow-up (>3 months). POC tests included VISITECT CD4 Advanced Disease, TB LAM Ag (Abbott), GeneXpert MTB/RIF (Cepheid), Histoplasma antigen LFA (MiraVista), and CrAg LFA (IMMY). Patients were followed at 30 and 90 days. Retrospective data for six months pre-study was collected for comparison.

Findings Among 419 PLHIV (55% cisgender men, 44% cisgender women, 1% transgender; mean age: 42 years, SD  $\pm$  11.1), 46% had confirmed OIs: TB (34%), cryptococcosis (12%), histoplasmosis (10%). Co-infections were frequent, with TB and histoplasmosis (44%). Cryptococcal meningitis and severe histoplasmosis were diagnosed in 5% and 6%, respectively. TB LAM was positive in 27% of tested patients, with 74% having disseminated TB. POC testing increased detection rates for TB, (1.8-fold) cryptococcosis (2.8-fold), and histoplasmosis (2.8-fold) compared to historical data. Survival rates were 87% at 30 days and 80% at 90 days, with cryptococcal antigenemia associated with higher mortality.

Interpretation POC testing improved OI diagnosis, aligning with WHO guidelines. These findings highlight the importance of integrating rapid diagnostics into HIV programs and the need for further research on long-term outcomes.

The Lancet Regional Health - Americas 2025;45: 101085 Published Online xxx https://doi.org/10. 1016/j.lana.2025. 101085

## **Received and a set of the set of**




#### Falci DR, Pasqualotto AC. Mycoses 2019; 62: 368-72



# Treatment





Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology

George R Thompson III, Thuy Le, Ariya Chindamporn, Carol A Kauffman, Ana Alastruey-Izquierdo, Neil M Ampel, David R Andes, Darius Armstrong-James, Olusola Ayanlowo, John W Baddley, Bridget M Barker, Leila Lopes Bezerra, Maria J Buitrago, Leili Chamani-Tabriz, Jasper F W Chan, Methee Chayakulkeeree, Oliver A Cornely, Cao Cunwei, Jean-Pierre Gangneux, Nelesh P Govender, Ferry Hagen, Mohammad T Hedayati, Tobias M Hohl, Grégory Jouvion, Chris Kenyon, Christopher C Kibbler, Nikolai Klimko, David C M Kong, Robert Krause, Low Lee Lee, Graeme Meintjes, Marisa H Miceli, Peter-Michael Rath, Andrej Spec, Flavio Queiroz-Telles, Ebrahim Variava, Paul E Verweij, Ilan S Schwartz, Alessandro C Pasqualotto

Thompson GR 3rd, et al. Lancet Infect Dis 2021; S1473-3099(21)00191-2 Perez F, et al. J Fungi 2021; 7:134



## 2 Treatment of histoplasmosis

2.1. Induction therapy (first line treatment): "Liposomal amphotericin B, 3.0 mg/kg for two weeks is the preferred treatment for severe or moderately severe disease." (conditional recommendation; very-low-certainty evidence)

Alternative Induction therapy: "In settings where liposomal amphotericin B is unavailable, deoxycholate amphotericin B, 0.7–1.0 mg/kg, is recommended for two weeks"

2.2. Maintenance therapy: "Itraconazole 200 mg three times daily for three days and then 200 mg twice daily is recommended for treating mild to moderate disease" (conditional recommendation; very-low-certainty evidence)

"Less than 12 months of therapy can be considered when the person is clinically stable, receiving antiretroviral therapy, has suppressed viral loads, and the immune status has improved" (conditional recommendation, very-low-certainty evidence)





## Single High Dose of Liposomal Amphotericin B in Human Immunodeficiency Virus/AIDS-Related Disseminated Histoplasmosis: A Randomized Trial

Alessandro C. Pasqualotto,<sup>1,2,0</sup> Daiane Dalla Lana,<sup>1</sup> Cassia S. M. Godoy,<sup>3,4</sup> Terezinha do Menino Jesus Silva Leitão,<sup>5,6</sup> Monica B. Bay,<sup>7,8</sup> Lisandra Serra Damasceno,<sup>5,6</sup> Renata B. A. Soares,<sup>3,4</sup> Roger Kist,<sup>2</sup> Larissa R. Silva,<sup>1</sup> Denusa Wiltgen,<sup>1,2</sup> Marineide Melo,<sup>9</sup> Taiguara F. Guimarães,<sup>3</sup> Marilia R. Guimarães,<sup>10</sup> Hareton T. Vechi,<sup>7</sup> Jacó R. L. de Mesquita,<sup>5</sup> Gloria Regina de G. Monteiro,<sup>7,8</sup> Antoine Adenis,<sup>11</sup> Nathan C. Bahr,<sup>12</sup> Andrej Spec,<sup>13</sup> David R. Boulware,<sup>14</sup> Dennis Israelski,<sup>15</sup> Tom Chiller,<sup>16</sup> and Diego R. Falci<sup>17,18</sup>

<sup>1</sup>Department of Clinical Medicine and Post-Graduation Program in Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil; <sup>2</sup>Infectious Diseases and Internal Medicine Services, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil; <sup>3</sup>Infectious Diseases Service, Hospital de Doenças Tropicais, Goiânia, Brazil; <sup>4</sup>Department of Research and Education, Pontifícia Universidade Católica de Goiás, Goiânia, Brazil; <sup>5</sup>Infectious Diseases Service, Hospital São José de Doenças Infecciosas, Fortaleza, Brazil; <sup>6</sup>Department of Public Health, Federal University of Ceará, Fortaleza, Brazil; <sup>7</sup>Department of Infectious Diseases, Federal University of Rio Grande do Norte, Natal, Brazil; <sup>8</sup>Infectious Diseases Service, Giselda Trigueiro Hospital and Instituto de Medicina Tropical do Rio Grande do Norte, Natal, Brazil; <sup>9</sup>Infectious Diseases, Service, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil; <sup>10</sup>Department of Nephrology, Universidade de São Paulo, São Paulo, Brazil; <sup>11</sup>Centre d'Investigation Clinique Antilles Guyane Inserm CIC1424, Centre Hospitalier de Cayenne, Cayenne, France; <sup>12</sup>Division of Infectious Diseases, Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA; <sup>13</sup>Division of Infectious Diseases, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA; <sup>14</sup>Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minnesota, USA; <sup>15</sup>International Medical Affairs, Global Patient Solutions, Gilead Sciences, San Francisco, California, USA; <sup>16</sup>Mycotic Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; <sup>17</sup>Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; and <sup>18</sup>Department of Clinical Medicine, Pontificia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

## *<b>RIAS*

### Single High-dose of Liposomal Amphotericin B in HIV/AIDS-related Disseminated Histoplasmosis: a **Randomized Trial**



#### Pasqualotto et al., 2023 | Clinical Infectious Diseases

Liposomal amphotericin is the drug of choice for disseminated histoplasmosis, but access is limited due to the high costs of the conventional long regimens.



				Single dose	10 m	ng/kg of L-AmB or	n D1, 3 mg/	kg of L-AmB daily	for 2
PARTICIPANTS: Adult people living with HIV, hospitalized and diagnosed with disseminated histoplasmosis, in six Brazilian tertiary medical centers.		10 mg/kg of L-AmB an		and 5	5 mg/kg of L-AmB on D3		weeks (control)		
			ALT THE		2X i   !!!!!-				
		Clinical response at day 14		84.0%	ARR = +10.5%	69.0%	ARR = -4.2%	74.0%	
METHODS		Currical response at day 14		04.070	95% CI [-7.7% - 28.7%]	07.070	95% CI [-24.8% - 16.3%]	74.070	
Prospective randomized multicenter open-label trial. Interventions: One or two-dose induction L-AmB therapy versus control (three arms), all followed by oral itraconazole therapy.	(	Overall survival at day 14		89.0%	ARR = -2.6% 95% CI [-15.6% - 10.4%]	78.0%	ARR = -13.7% 95% CI [-29.5% - 2.1%]	89.7%	
	1	1-year overall survival		73.7%		65.8%		76.9%	
	હિરુ	Nephrotoxicity at day 14 (any AKI criteria)		11.8%		26.7%		29.7%	


One day induction therapy with 10 mg/kg of L-AmB in AIDS-related histoplasmosis was safe. A phase III clinical trial is needed to confirm clinical response. A singledose regimen would markedly reduce drug-acquisition costs and shorten and simplify treatment, which are key points in terms of increased access.

Clinical	Infectious	Diseases
Chinear	111100010000	21000000

https://doi.org/10.1093/cid/ciad313

## **RAS Induction trial**

Randomized, multicenter (16 centers), open-label study in Brazil



Non-inferiority trial with a 90% power to detect a margin of 10% with a two-tailed p-alpha of 5% If non-inferiority is reached, the study will be tested for superiority

## **SIAS DOOR outcome - Secondary endpoint**

• Evaluated on D14 by a blinded external committee

(i) Death within the first 2 weeks of randomization


(ii) Death within the 10-week follow-up period

(iii) Grade 4 laboratory abnormality in the first 2 week

(iv) Grade 3 laboratory abnormality in the first 2 weeks

(v) Survival at week 10

# *RAS Factorial trial*



n=664

**Study Pis:** Nathan Bahr and Alessandro C. Pasqualotto

**<b>RIAS** 

CORRESPONDENCE

# Fungal diseases are not in the radar of main international HIV conferences

do Nascimento, Anderson A.A.<sup>a</sup>; Pasqualotto, Alessandro C.<sup>a,b</sup>

Author Information  $\otimes$ 

AIDS 39(1):p 99-100, January 01, 2025. | DOI: 10.1097/QAD.0000000000004060

0.8% only
International AIDS Conference
IAS Conference
CROI
EACS



# Thank you

# pasqualotto@ufcspa.edu.br +55 51 999951614 Twitter: @PasqualottoAle